Sirnaomics of Rockville, MD plans to begin a Phase I trial of its lead drug candidate in China during the year 2008. The molecule, called STP601, uses an RNA interference mechanism to target neovascularization in the eye. If Sirnaomics achieves its goal of starting a trial that soon, it would be a remarkable achievement because Sirnaomics is a very young company – it was formed earlier this year – and it has not depended on in-licensing any technology to speed its forward progress. In an exclusive interview, Dr. Lu, CEO of the company, talks about the future of the company. More details...

Stock Symbol (NYSE: NVS)